araag2/HINT huggingface dataset:
Clinical trial NCT02589145 (phase 1/phase 2, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: lenalidomide, vorinostat, gemcitabine, busulfan, melphalan, rituximab, dexamethasone, caphosol, glutamine, pyridoxine, enoxaparin, palifermin
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CS(=O)(=O)OCCCCOS(C)(=O)=O, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CC[C@H](C)[C@H](N)C(O)=O, CC1=C(O)C(CO)=C(CO)C=N1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Reason stopped: 
    closed due to very slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          1. Age 15-65

          2. Patients with ABC (determined by immunohistochemistry using the Hans algorithmI) DLBCL
             with primary refractory disease, relapse <12 months after initial therapy, secondary
             International Prognostic Index (IPI) >1, less than partial response to salvage
             treatment or exposure to >3 salvage regimens

          3. Adequate renal function, as defined by an estimated serum creatinine clearance >/= 50
             ml/min (MDRD method) and/or serum creatinine </= 1.8 mg/dL

          4. Adequate hepatic function (SGOT and/or SGPT </= 3 x ULN; bilirubin and ALP </= 2 x ULN

          5. Adequate pulmonary function with FEV1, FVC and DLCO (corrected for Hgb) >/= 50%

          6. Adequate cardiac function with left ventricular ejection fraction >/= 40%. No
             uncontrolled arrhythmias or symptomatic cardiac disease

          7. ECOG performance status <2

          8. Negative Beta HCG in woman with child-bearing potential

          9. All study participants must be registered into the mandatory Revlimid REMS program,
             and be willing and able to comply with the requirements of the REMS program.

         10. Females of reproductive potential must adhere to the scheduled pregnancy testing as
             required in the Revlimid REMS program.

        Exclusion Criteria:

          1. Grade >/= 3 non-hematologic toxicity from previous therapy that has not resolved to
             </= G1

          2. Prior whole brain irradiation

          3. Active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA >/= 10,000
             copies/mL, or >/= 2,000 IU/mL)

          4. Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic
             hepatitis C or positive hepatitis C serology

          5. Active infection requiring parenteral antibiotics

          6. HIV infection, unless receiving effective antiretroviral therapy with undetectable
             viral load and normal CD4 counts

          7. Radiation therapy in the month prior to enrollment

          8. History of arterial thromboembolic events in the past 3 months and of venous
             thromboembolic events in the past month

          9. History of hypersensitivity of lenalidomide or thalidomide
Clinical trial NCT02593760 (phase 1, status: completed)
Conditions: myelofibrosis
ICD codes: D75.81, C94.41, C94.42, C94.40
Drugs: ruxolitinib, vismodegib
SMILES: N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1, CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologically confirmed diagnosis of primary MF, post-polycythemia vera MF, or
             post-essential thrombocythemia MF, according to the 2008 revised World Health
             Organization criteria

          -  Intermediate-1, intermediate-2, or high-risk according to the IWG-MRT Dynamic
             International Prognostic Scoring System

          -  Life expectancy >= 6 months

          -  Peripheral blood blast count of less than (<) 10%

          -  Palpable splenomegaly of greater than (>) 5 centimeters (cm) below the left costal
             margin

          -  Eastern Cooperative Oncology Group performance status of 0 to 2

          -  Adequate hepatic and renal function

        Exclusion Criteria:

          -  Prior treatment with a Hedgehog or Janus kinase pathway inhibitor

          -  Treatment with strong cytochrome P450 3A4 inhibitors/inducers within 28 days prior to
             Day 1

          -  Prior therapy for the treatment of intermediate- or high-risk MF including
             chemotherapy, interferon, thalidomide, busulfan, lenalidomide, anagrelide, or
             androgens within 28 days prior to Day 1

          -  Prior splenectomy or splenic irradiation

          -  Inadequate bone marrow reserve

          -  Participants with any history of platelet counts of < 50,000/mccL or ANC of < 500/mL,
             except during treatment for myeloproliferative neoplasm or treatment with cytotoxic
             therapy for any other reason

          -  Planned allogeneic bone marrow transplant during the study
Clinical trial NCT02597400 (phase 1, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: metformin, hms5552
SMILES: CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and/or female subjects between the ages of 18 and 70 years

          -  Body Mass Index (BMI) of approximately 22 to 38kg/m2

          -  HbA1c ≥7% and ≤12%

          -  Are capable of giving informed consent and complying with study procedures

        Exclusion Criteria:

          -  fasting blood glucose ≤110 or ≥270mg/dL

          -  Type 1 diabetes mellitus, or latent autoimmune diabetes in adults

          -  History or symptoms of clinically significant cardiovascular disease, particularly
             coronary artery disease, arrhythmias, atrial tachycardia, or congestive heart disease
             within one year of screening

          -  History of liver disease and clinically significant renal disease

          -  Known hypersensitivity to metformin hydrochloride;

          -  Positive pregnancy test result;
Clinical trial NCT02603861 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: ly3154207, placebo, modafinil
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Overtly healthy males 18 years of age or older who have given consent and are reliable
             and willing to make themselves available for the duration of the study and are willing
             to follow study procedures

          -  Have a regular sleep pattern with routine time spent in bed between 6.5 hours and 9
             hours each night

        Exclusion Criteria:

          -  Are shift workers who shifted work within 14 days prior to screening or plan to during
             the study

          -  Have a known sleep disorder or history of a sleep disorder

          -  Have traveled 2 time zones or more within 7 days prior to screening or plan to during
             the study

          -  Regularly take naps during the day

          -  Are hearing impaired
Clinical trial NCT02603952 (phase 1/phase 2, status: completed)
Conditions: influenza
ICD codes: J11.81, J11.82, J10.01, J10.81, J10.82, J11.08, J11.2
Drugs: oseltamivir, medi8852, placebo
SMILES: CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 through 65 years at the time of screening.

          -  Symptomatic presumptive Influenza A infection with onset of symptoms less than or
             equal to (≤) 5 days prior to MEDI8852 administration and defined as the presence of:

          -  Fever of greater than or equal to (≥) 38.0 degrees Celsius (100.4 degrees Fahrenheit)
             at screening AND

          -  ≥ 1 moderate systemic symptom (headache, malaise, myalgia, sweats and/or chills, or
             fatigue) AND

          -  ≥ 1 moderate respiratory symptom (cough, sore throat, or nasal symptoms)

          -  Influenza A infection confirmed with positive rapid antigen test

          -  Able to complete the follow-up period through Day 101 as required by protocol
             (including telephone follow-up for Days 11 to 101)

          -  Females of childbearing potential who are sexually active with a nonsterilized male
             partner must use a highly effective method of contraception for at least 2 days prior
             to the first dose of investigational product and must agree to continue using such
             precautions through Day 101 of the study

        Exclusion Criteria:

          -  Hospitalized subjects.

          -  Receipt of influenza antiviral therapy within the preceding 14 days.

          -  Receipt of immunoglobulin or blood products within 6 months prior to screening.

          -  Known immunodeficiency due to illness, including human immunodeficiency virus (HIV),
             or due to drugs, including any course of glucocorticoid therapy exceeding 2 weeks of
             prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months
             prior to screening.

          -  Current clinical evidence of pneumonia.

          -  Active bacterial infection requiring treatment with oral or parenteral antibiotics.

          -  History of malignancy other than treated non-melanoma skin cancers or locally-treated
             cervical cancer in previous 3 years.

          -  Any planned surgical procedure before completion of Day 101.
Clinical trial NCT02604719 (phase 1/phase 2, status: unknown status)
Conditions: postpartum hemorrhage
ICD codes: O72.1, O72.2
Drugs: tranexamic acid and ethamsylate
SMILES: NC[C@H]1CC[C@@H](CC1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Women undergoing elective caesarean section

          2. Patient having one or more risk factor for PPH

               -  Multiple pregnancy

               -  Polyhydramnios (AFI >25cm)

               -  Macrocosmic baby (>4.5 Kg)

               -  Prolonged , augmented and obstructed labour

               -  Obese patients(BMI >30)

               -  Premature rapture of membranes

               -  Previous history of PPH

          3. Age ≥18 years

          4. Gestational Age ≥ 35 Weeks

          5. Informed Oral Consent From The Patient

        Exclusion Criteria:

          1. History of venous thrombosis (DVT and/or Pulmonary embolism) OR arterial thrombosis
             (angina pectoris , myocardial infarction, stroke)

          2. History of epilepsy or seizure

          3. Any Known Cardiovascular , renal or liver Disease

          4. Autoimmune Diseases

          5. Sickle Cell Disease

          6. Severe hemorrhagic Disease

          7. Placenta Previa.

          8. Morbidly adherent Placenta

          9. Abruptio placenta

         10. Eclampsia, hemolysis, elevated liver enzymes, and low platelet count syndrome

         11. Administration Of low molecular weight heparin or Anti platelets the week before
             delivery .
Clinical trial NCT02608437 (phase 1, status: unknown status)
Conditions: metastatic melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: sgi-110, ipilimumab
SMILES: NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](COP(O)(=O)O[C@H]2C[C@@H](O[C@@H]2CO)N2C=NC(N)=NC2=O)O1, COC1=CC=CC=C1OCC(O)CO
Eligibility criteria:

        Inclusion Criteria:

          -  Willing and able to give written informed consent

          -  Unresectable Stage III or Stage IV melanoma with measurable lesions by CT or MRI per
             mWHO/irRC criteria, that can be amenable to biopsy

          -  Previously treated or untreated; prior therapy may include chemotherapy or targeted
             therapy for metastatic disease (i.e., BRAF and/or MAP-ERK kinase (MEK) inhibitor).
             Prior adjuvant interferon is permitted

          -  Subjects with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

          -  4 weeks or greater since last treatment

          -  Must have recovered from any acute toxicity associated with prior therapy

          -  Life expectancy greater than 16 weeks

          -  Negative screening tests for HIV, Hepatitis B, and Hepatitis C

          -  Women of child-bearing potential must not be pregnant or breastfeeding, must have a
             negative pregnancy test at Screening and all men must be practicing two medically
             acceptable methods of birth control. Men should not father a child while receiving
             treatment with SGI-110 + ipilimumab, and for 2 months following completion of
             treatment. Men with female partners of childbearing potential should use effective
             contraception during this time

        Exclusion Criteria:

          -  Subjects with any contraindications for ipilimumab

          -  Subjects with active brain metastases or leptomeningeal metastases

          -  Subjects with metastatic uveal melanoma

          -  Subjects with active, known or suspected autoimmune disease

          -  Subjects with a condition requiring systemic treatment with either corticosteroids
             (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14
             days of treatment

          -  Subjects with symptomatic effusions on account of pleural, pericardial metastases of
             melanoma

          -  Prior treatment with an anti-Programmed Death receptor-1 (PD-1), anti-Programmed
             Death-1 ligand-1 (PD-L1), anti-PD-L2, or anti-CTLA-4 antibody

          -  Subjects who had major surgery or radiation therapy within 21 days of starting
             treatment

          -  Subjects who are unable to return for follow-up visits as required by this study

        Other Exclusion Criteria:

          -  Prisoners or subjects who are involuntarily incarcerated

          -  Subjects who are compulsorily detained for treatment of either a psychiatric or
             physical (e.g., infectious disease) illness.
Clinical trial NCT02612246 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: glpg1972 single ascending doses, placebo single dose, glpg1972 multiple ascending doses, placebo multiple doses
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males between 18-50 years of age

          -  Subjects must have a body mass index between 18-30 kg/m²

          -  Subjects must be judged to be in good health based upon the results of a medical
             history, physical examination, vital signs, 12-lead electrocardiogram and laboratory
             profile

        Exclusion Criteria:

          -  A subject with a known hypersensitivity to study drug ingredients or a significant
             allergic reaction to any drug

          -  Concurrent participation or participation within 8 weeks prior to the initial study
             drug administration in a drug/device investigational research study

          -  A subject with active drug or alcohol abuse within 2 years prior to the initial study
             drug administration

          -  Current sexually active (and/or child wish) male; a contraception method should be
             used
Clinical trial NCT02614586 (phase 1, status: terminated)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: tak-058, ondansetron, tak-058 placebo, ondansetron placebo
SMILES: CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
Eligibility criteria:

        Inclusion Criteria:

          1. 18 to 60 years of healthy and schizophrenic participants, inclusive, at the time of
             informed consent.

          2. Has acceptable clinical laboratory evaluations (including clinical chemistry,
             hematology and complete urinalysis).

          3. Meets schizophrenia criteria as defined by the Diagnostic & Statistical Manual of
             Mental Disorders, 5th Edition (DSM-V).

          4. Are on a stable dose of single second-generation antipsychotics (SGA) for at least 2
             months prior to Screening as documented by medical history and assessed by site staff.

          5. Demonstrates Positive and Negative Syndrome Scale (PANSS) total score of less than
             equal to (<=) 85.

          6. Has a P50 ratio of > 0.5 at both screening assessments.

        Exclusion Criteria:

          1. Has a history in the last year or currently receiving treatment with clozapine or
             olanzapine.

          2. Has taken any excluded medications, supplements or food products.

          3. Has a history of gastrointestinal disease that would influence the absorption of study
             drug or have a significant medical history of any disease that would contraindicate
             the administration of TAK-058, ondansetron, or a similar compound.

          4. Has substance abuse or dependence within previous 12 months, unstable mood or anxiety
             disorder.

          5. Has a current diagnosis of a significant psychiatric illness other than schizophrenia
             per DSM-V and is in an acute phase/episode.

          6. Has clinically meaningful hearing loss per investigator's judgment.
Clinical trial NCT02622932 (phase 1, status: completed)
Conditions: advanced solid tumors
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: anlotinib and 14c-labeled anlotinib
SMILES: COC1=CC2=C(OC3=CC=C4NC(C)=CC4=C3F)C=CN=C2C=C1OCC1(N)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  signed and dated informed consent

          -  histologically or cytologically confirmed diagnosis of advanced solid tumor (including
             RCC、NSCLC、STS and CRC)

          -  failed to the treatment of line 1 or 2

          -  ECOG PS:0-1,Life expectancy of more than 3 months

          -  main organs function is normal

        Exclusion Criteria:

          -  prior treatment with Anlotinib or Allergic to drug or its formulation ingredients

          -  subjects with the gastrointestinal tract, liver and kidney disease of affect drug
             absorption and metabolism

          -  CTCAE(4.0) Grade 1 or higher non-remission toxicity induced by any other previous
             treatments

          -  patients with pleural effusion or ascites, causing respiratory syndrome (CTCAE Grade 2
             or higher dyspnea [Grade 2 dyspnea refers to Shortness of breath with a small amount
             of activities, affecting Instrumental activities of daily life])

          -  patients underwent major surgical treatment，open biopsy or significant traumatic
             injury within 28 days prior to assignment
Clinical trial NCT02624089 (phase 1/phase 2, status: unknown status)
Conditions: appendicitis
ICD codes: K36, K37, K35.80, K35.20, K35.21, K35.890, K35.891
Drugs: ropivacaine, normal saline
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, O
Eligibility criteria:

        Inclusion Criteria:

          -  Children and adolescents aged 7-18 years old

          -  ASA Score I (American Society of Anesthesiologists classification) [Appendix 1]: a
             normal healthy patient.

          -  ASA Score II (American Society of Anesthesiologists classification): A patient with
             mild systemic disease

          -  Patients scheduled for laparoscopic appendectomy surgery

          -  Uncomplicated appendicitis

               -  Hemodynamically stable patient

               -  No evidence of appendiceal perforation based on preoperative clinical and imaging
                  assessment

               -  Diagnosed to have simple acute appendicitis by intraoperative laparoscopy

          -  Patients who have provided a written informed assent

          -  Caregivers who have provided a written informed consent

        Exclusion Criteria:

          -  ASA Score III (American Society of Anesthesiologists classification): A patient with
             severe systemic disease

          -  ASA Score IV (American Society of Anesthesiologists classification): A patient with
             severe systemic disease that is a constant threat to life

          -  ASA Score V (American Society of Anesthesiologists classification): A moribund patient
             who is not expected to survive without the operation

          -  Hemodynamically unstable patient

          -  Evidence of appendiceal perforation on based on preoperative clinical and imaging
             assessment

          -  Perforated or gangrenous appendicitis diagnosed during laparoscopic surgery

          -  Postoperative admission in an intensive care unit with sedation or ventilatory
             assistance

          -  Cognitive impairment or mental retardation

          -  Progressive degenerative diseases of the CNS

          -  Seizures or chronic therapy with antiepileptic drugs

          -  Severe hepatic or renal impairment

          -  Allergy to one of the specific drugs under study

          -  Alcohol or drug addiction

          -  Failure to successfully undergo a laparoscopic appendectomy

          -  A significant communication problem including language barrier, precluding phone
             follow up

          -  Participation in a concomitant research study

          -  Inability to assure complete follow up

          -  Failure to acquire informed consent and assent